Biorestorative Therapies Inc (BRTX) Stock Price, Quote & News

Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral di...

Industry: Biotechnology

Sector: Healthcare

Phone: 631 760 8100

Website: www.biorestorative.com

Address:

40 Marcus Drive, Suite 1, Melville, United States

daytraderforplayandprofi Sep. 30 at 7:04 AM

$BRTX

0 · Reply

KFC0115 Sep. 29 at 3:43 PM

$BRTX waiting for good news

0 · Reply

Hernandrod12 Sep. 29 at 12:42 PM

$AMS $QURE $BRTX $PHAT

0 · Reply

GluttonBoy Sep. 29 at 12:38 AM

$AMS Micro float making a big move up , Looks like it could run up 100% tomorrow - keep it on watch $QURE FDA Approval coming? Biotech gem 💎 $BRTX $5 target $PHAT Insiders own 60%+ looking for potential entries.

0 · Reply

LegendaryCharts Sep. 29 at 12:08 AM

$PAVS Micro float making a big move up , Looks like it could run up 100% tomorrow - keep it on watch $EYEN UFD update? $BRTX Going to 5 soon $PHAT Insiders own 60%+

1 · Reply

KFC0115 Sep. 27 at 9:44 AM

$BRTX looking for $2

0 · Reply

Smilkky Sep. 26 at 9:39 AM

$BRTX any news from the meeting?

0 · Reply

daytraderforplayandprofi Sep. 18 at 9:06 PM

$BRTX

0 · Reply

Black_Jobs Sep. 18 at 11:19 AM

$BRTX Zero Debt. $6 million cash on hand. No dilution. 2 million dollar share buyback coming. WHY ISN'T THIS $5 AT LEAST?

0 · Reply

JMVaderTrader Sep. 17 at 11:10 PM

$BRTX - BioRestorative Therapies Here is what I see: Float: 7.64M OS: 7.98M Dilution: Existing Open Offerings/shelfs/warrants February 2024 Warrants - Registered Remaining Warrants Outstanding 2,513,685 Exercise Price - $2.43 November 2021 Uplist Warrants - Registered Remaining Warrants Outstanding 805,420 Exercise Price - $2.33 Aged Convertible Preferred Remaining Shares to be Issued When Converted - 1,398,158 Conversion Price - $10.00 November 2024 Rodman & Renshaw ATM - Registered Remaining ATM Capacity - $2,530,170 Shelf - February 2023 Shelf - Registered Current Raisable Amount - $2,112,608

0 · Reply

BioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:30 PM EDT - 2 months ago

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

Jun 18, 2025, 9:35 AM EDT - 3 months ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

Jun 17, 2025, 9:25 AM EDT - 3 months ago

BioRestorative Announces Share Repurchase Program

Jun 13, 2025, 7:45 AM EDT - 4 months ago

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

Jun 9, 2025, 7:45 AM EDT - 4 months ago

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

May 14, 2025, 8:46 PM EDT - 5 months ago

BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript

May 13, 2025, 9:15 AM EDT - 5 months ago

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

May 8, 2025, 4:30 PM EDT - 5 months ago

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

May 7, 2025, 9:15 AM EDT - 5 months ago

BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025

Apr 15, 2025, 8:30 AM EDT - 6 months ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

Apr 10, 2025, 9:15 AM EDT - 6 months ago

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

Mar 27, 2025, 8:10 PM EDT - 6 months ago

BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:45 AM EST - 7 months ago

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

Feb 26, 2025, 8:15 PM EST - 7 months ago

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

Feb 20, 2025, 8:30 AM EST - 8 months ago

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

Dec 5, 2024, 6:45 AM EST - 10 months ago

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

Nov 13, 2024, 7:53 PM EST - 11 months ago

BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:10 AM EST - 11 months ago

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

Oct 3, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 19, 2024, 6:55 AM EDT - 1 year ago

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

Aug 13, 2024, 11:26 PM EDT - 1 year ago

BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript

Jul 23, 2024, 7:10 AM EDT - 1 year ago

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

Jun 27, 2024, 7:40 AM EDT - 1 year ago

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

Jun 17, 2024, 7:05 AM EDT - 1 year ago

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

Jun 13, 2024, 7:00 AM EDT - 1 year ago

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

Jun 4, 2024, 8:50 AM EDT - 1 year ago

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

May 24, 2024, 7:45 PM EDT - 1 year ago

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

May 15, 2024, 9:00 AM EDT - 1 year ago

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

May 14, 2024, 7:08 PM EDT - 1 year ago

BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:10 PM EDT - 1 year ago

BioRestorative Therapies Provides First Quarter 2024 Business Update

May 8, 2024, 7:30 AM EDT - 1 year ago

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

Apr 30, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 30, 2024, 7:30 AM EDT - 1 year ago

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

Apr 16, 2024, 7:45 AM EDT - 1 year ago

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

Apr 8, 2024, 7:45 AM EDT - 1 year ago

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Apr 3, 2024, 4:38 PM EDT - 1 year ago

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

Apr 1, 2024, 7:45 AM EDT - 1 year ago

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Mar 11, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

Feb 14, 2024, 9:15 AM EST - 1 year ago

BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting

Feb 6, 2024, 8:05 AM EST - 1 year ago

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

Feb 5, 2024, 7:30 AM EST - 1 year ago

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

Feb 1, 2024, 7:30 AM EST - 1 year ago

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

Dec 12, 2023, 9:15 AM EST - 1 year ago

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

Oct 9, 2023, 12:10 PM EDT - 2 years ago

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

Sep 18, 2023, 9:00 AM EDT - 2 years ago

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

Sep 12, 2023, 9:00 AM EDT - 2 years ago

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

Sep 8, 2023, 8:30 AM EDT - 2 years ago

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

Aug 30, 2023, 9:00 AM EDT - 2 years ago

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

Aug 2, 2023, 9:00 AM EDT - 2 years ago

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

daytraderforplayandprofi Sep. 30 at 7:04 AM

$BRTX

0 · Reply

KFC0115 Sep. 29 at 3:43 PM

$BRTX waiting for good news

0 · Reply

Hernandrod12 Sep. 29 at 12:42 PM

$AMS $QURE $BRTX $PHAT

0 · Reply

GluttonBoy Sep. 29 at 12:38 AM

0 · Reply

LegendaryCharts Sep. 29 at 12:08 AM

$PAVS Micro float making a big move up , Looks like it could run up 100% tomorrow - keep it on watch $EYEN UFD update? $BRTX Going to 5 soon $PHAT Insiders own 60%+

1 · Reply

KFC0115 Sep. 27 at 9:44 AM

$BRTX looking for $2

0 · Reply

Smilkky Sep. 26 at 9:39 AM

$BRTX any news from the meeting?

0 · Reply

daytraderforplayandprofi Sep. 18 at 9:06 PM

$BRTX

0 · Reply

Black_Jobs Sep. 18 at 11:19 AM

$BRTX Zero Debt. $6 million cash on hand. No dilution. 2 million dollar share buyback coming. WHY ISN'T THIS $5 AT LEAST?

0 · Reply

JMVaderTrader Sep. 17 at 11:10 PM

0 · Reply

daytraderforplayandprofi Sep. 17 at 7:38 PM

$BRTX good entry point

0 · Reply

Love_To_Learn Sep. 12 at 10:45 AM

$BRTX made a change to u just b4 beud * beud is BDRX u do share some signature

0 · Reply

Bridge_Four Sep. 10 at 3:52 PM

$BRTX taking my loss and moving on

1 · Reply

cannabischickin2772 Sep. 9 at 1:56 PM

$PRFX $BRTX have hit me hard oh well😞

1 · Reply

Smilkky Sep. 8 at 5:37 PM

$BRTX watching.

0 · Reply

Bridge_Four Sep. 8 at 5:18 PM

$BRTX zero volume

0 · Reply

NVDAMillionaire Sep. 5 at 4:25 PM

$BRTX Excellent article that nails exactly where BRTX stands right now. So if you want to update your BRTX knowledge or get acquainted with BRTX, this is a must read. https://beyondspx.com/quote/BRTX/biorestorative-therapies-autologous-innovation-and-commercial-ascent-drive-a-regenerative-future-nasdaq-brtx#analysis

1 · Reply

cannabischickin2772 Sep. 5 at 1:50 PM

$PRFX $BRTX have crushed me…wtf

0 · Reply